Introduction
As the most common type of leukemia in adults, acute myeloid leukemia (AML) is a malignant clone disease of the hematopoietic system. Although there have been great advances in the treatment of AML, patients have highly heterogenous clinical course and their long-term prognosis is still dismal [
1]. Therefore, identifying novel prognostic markers to improve the existing molecular-based stratification and risk-adapted therapy for AML patients is urgently required.
It is well known that microRNAs (miRNAs) have been implicated in both biological and pathological processes such as cell growth, apoptosis, migration and invasion. There is an increasing body of evidence unraveling the molecular mechanism of miRNAs as either oncogenes or tumor suppressors in human cancers, which is mostly depending on the function of their different target genes and specific tumor microenvironment [
2]. Aberrantly expressed miRNA patterns with clinical prognostic significance have been reported in AML patients [
3]. For instance, in a cohort of 176 AML patients from TCGA database, the data of miRNAs sequencing and gene microarray were analyzed to identify risk miRNAs with prognostic value. Among the 705 miRNAs that were studied, upregulated miR-520a, 599, 606, 137 and 362 predicted unfavorable outcomes of AML patients [
4]. In another study of 187 cytogenetically normal AML (CN-AML) patients, miR-181a overexpression was strongly correlated with better survival [
5].
The miR-17-92 cluster, known as OncomiR-1, is a highly conserved polycistronic transcript among vertebrates, which is located on the open reading frame 25 of chromosome 13 (C13orf25) and yields six mature miRNAs (miR-17, 18a, 19a, 20a, 19b, and 92a) [
6]. Accumulating evidence have revealed that the members of miR-17-92 family are very often dysregulated and play critical roles in a wide range of cancer types including osteosarcoma, hepatocellular carcinoma, renal cancer, ovarian cancer, lymphoma, retinoblastoma and so on [
7]. Whereas, the expression and prognostic significance of miR-17 in AML has not been fully investigated. In current study, we aimed to evaluate the expression and clinical significance of miR-17 in de novo AML patients.
Discussion
In current study, we explored the prognostic value of miR-17 in de novo AML for the first time. The results showed that miR-17 frequently overexpressed in AML patients, which was significantly related to poor CR rate and shorter OS. Cases with high miR-17 levels had a lower frequency of CEBPA double mutation and less favorable risk according to ELN risk stratification. The follow-up of 31 patients achieved CR and 8 relapse patients revealed that miR-17 expression significantly decreased after successful induction chemotherapy and returned to primary level even higher when in relapse phase. Moreover, the gene expression profile of miR-17 involved in multiple biological functions and signal pathways. By bioinformatics analysis, we found FGL2, PLAUR, SLC2A3, GPR65, CTSS, TLR7, S1PR3, OGFRL1, LILRB1, IL17RA, SIGLEC10, SLAMF7, PLXDC2, HPSE, TCF7 and MYCL as direct targets of miR-17 among the DEGs. These results suggested that miR-17 might function as independent prognostic biomarker and predict disease recurrence for AML patients.
The miR-17∼92 cluster has been reported to be crucial for vertebrate development such as lymphocyte maturation [
9], skeletal development [
10], epithelial proliferation and branching [
11]. Targeted deletion of miR-17∼92 in mice leads to early neonatal lethality with ventricular septal defects, lung hypoplasia, and B lymphopoiesis inhibition [
12]. Accordingly, the miR-17∼92 cluster is involved in cardiovascular, neurodegenerative and immune diseases [
13‐
15]. Other than the involvement in normal development described above, the majority of the previous studies have demonstrated the potential oncogenic role of miR-17∼92 cluster in various cancers. For instance, in retinoblastoma, miR-17∼92 acted as an
RB-collaborating gene to promote retinoblastoma, in part by regulating p21Cip1 and p57Kip [
16]. In colon cancer, miR-17 induced epithelial-mesenchymal transition and the formation of a stem cell-like population through the modulation of CYP7B1 expression [
17]. In lung cancer, miR-17-5p was overexpressed and correlated with poor survival of patients [
18]. In B-cell chronic lymphocytic leukemia (CLL), the miR-17∼92 cluster members were highly amplified, among which four (miR-17, miR-20a, miR-18a and miR-19b) and five (miR-17, miR-20a, miR-18a, miR-19a and miR-19b) members were significantly induced by CD154 and stromal cell culture, respectively [
19]. Moussay et al
. proved circulating miR-20a was a reliable classifier to distinguish CLL patients from healthy controls (AUC = 0.920) and associated well with the disease severity (
P = 0.0242) [
19]. The miR-17/92 cluster was also found overexpressed in B-cell Lymphomas, and the individual members miR-19a/19b were required and sufficient for the B-cell lymphoma tumorigenesis [
20,
21].The study performed by Meenhuis A found miR-17/20 in combination with two other miRNAs promoted expansion and replating capacity of myeloid progenitors by targeting sequestosome 1–regulated pathways [
22]. In another study, Li et al
. showed miR-17/20 was particularly amplified in MLL-rearrangement AML patients [
23]. However, there is some evidence that miR-17 also possesses antitumor properties. Aberrant low expression of miR-17, consistent with the high frequency loss of heterozygosity and deletions at 13q31.3, has been reported in several types of cancers [
24,
25]. For example, in prostate cancer, miR-17 has been demonstrated to attenuate androgen receptor signaling and cell growth by targeting proto-oncogenic transcriptional activator PCAF [
26]. In oral squamous cell carcinoma, miR-17 functioned as a tumor suppressor via regulating KPNA2/PI3K/AKT axis [
27].
Here, we reported that miR-17 predicted poor prognosis and added to the prognostic value of various previously identified molecular indicators in AML, such as TP53, CEBPA, NPM1, FLT3-ITD and so on. In our study, APL patients were not enrolled, considering that it has shifted to a highly curable AML subtype with its own typically different genetic characteristics, risk stratification and target-therapy. The role of miR-17 as prognostic factor was not restricted to CN-AML but proved in a highly mixed population of AML including patients with old age and cytogenetic abnormalities. There was significant difference only in CEBPA double mutation between the high and low miR-17 groups. Though the regulation of CEBPA expression by miR-17 had been reported in several studies [
28,
29], how miR-17 influences CEBPA double mutation is not fully illuminated. In line with our results, previous study found no significant association between miR-17 and NPM1 or FLT3 mutation status in AML patients [
30]. In addition, there was evidence showing that miR-17 ~ 92 cluster contributed to the MEIS1/HOXA9-mediated transformation of MLL leukemia [
31]. MLL is involved in over 100 different recurrent rearrangements, of which greater than 70 translocation partner genes (TPGs) have now been identified [
32,
33]. Despite the vast number of partner genes, only nine TPGs (AF4, AF9, ENL, AF10, AF6, ELL, AF1P, AF17 and SEPT6) seem to be predominantly recombined to MLL. In our study, we detected MLL-partial tandem duplications (MLL-PTD) and eleven MLL-related fusion (MLL-AF9, MLL-AF4, MLL-ENL, MLL-AF10, MLL-SEPT6, MLL-ELL, MLL-AF17, MLL-AF1q, MLL-AF1p, MLL-AF6, MLL-AFX). In accordance with previous reports [
34,
35], two of the four (50%) cases with MLL-related abnormalities were classified as M5 category indicating the commonly association with monocytic leukemias. The four MLL-related aberrations (including two MLL-PTD mutations and two MLL-related fusions) were exclusively found in high miR-17 group but unfortunately outside the significance level. The presence of distinct MLL lesions in AML is widely considered as an independent dismal prognostic factor despite improved regimen options like allogeneic hematopoietic stem cell transplantation appealing for novel effective regimens [
36,
37]. Interestingly, the colony forming ability of MLL-fusion containing cells could be dramatically abolished in response to treatment with antagomir-17 [
31]. Whether, therapy targeting miR-17 can benefit AML patients especially with the MLL-related aberrations or M5 subtype needs further study.
To derive biological insights into the oncogenic mechanism of miR-17 in AML, gene-expression profiling signature characteristic of miR-17 was analyzed. Bioinformatics data showed that those miR-17-associated genes were involved in hematopoietic cell lineage, transcriptional mis-regulation and pathways in AML. We found a negative correlation between miR-17 expression with sixteen miR-17-targeted genes among the DEGs. Notably, there were seven targets of miR-17 (PTAFR, TLR7, S1PR3, GPR65, CTSS, PLAUR and SLC2A3) identified as hub genes in the MCODE modules. Among them, PTAFR is a platelet-activating factor and involved in a wide range of human functions. The membrane expression of PTAFR, resulted from cell maturation and differentiation, was a marker of mature cells and rarely observed in AML blasts [
38]. Fiedler ERC et al. have proved that PAFR could sensitize CML cells to the dasatinib treatment after binging with PAF [
39]. Another previous study revealed PTAFR as a promising target for tumor repopulation induced by radiotherapy in solid tumor [
40]. TLR7, namely Toll‐like receptor 7, was enriched into Toll-like receptor signaling pathway, inflammatory response and innate immune response. Ge F et al. have demonstrated TLR7 as a novel DNA methylation prognostic signature for AML patients who might benefit from TLR7‐based immunosuppressive therapy [
41]. S1PR3, as an inflammation-activated S1P receptor, not only governed the myeloid fate in normal hematopoiesis via the TNFα–NF-κB axis, but also predicted prognosis in human AML [
42]. GPR65, a member of purine receptor family, has been reported to suppress hematopoiesis by establishing repressive chromatin, repressing Gata2 transcription and thus inhibiting GATA-2-GPCR circuit [
43]. CTSS, as lysosomal globular proteases, participated in various biological processes including immune response, neutrophil degranulation, proteolysis and so on. As summarized in a systematic review, the prognostic value of CTSS remains controversial in leukemia [
44]. PLAUR, also known as CD87, has shown poor survival benefits in leukemias, with the potential to be used as a target for fusion protein therapy of PLAUR-expressing AML [
45,
46]. SLC2A3, a regulator of early embryonic development, contributes to glucose transport and participates in multiple pathways [
47]. Available evidence proved that low expression of SLC2A3 predicted poor response of demethylation and vitamin C, which had a worse effect on OS in AML [
48]. Taken together, the gene-expression profiling associated with miR-17 might provide mechanistic insights into the clinical prognostic significance of miR-17 in AML.
In conclusion, our study revealed that miR-17 was upregulated in de novo AML patients, and its high expression pointed to dismal clinical outcome and disease recurrence. MiR-17 expression might serve as a novel independent prognostic biomarker for AML patients. Further studies are required to explore the biological roles of miR-17 and its target genes in AML.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.